LIONVILLE, PA. (April 14, 2011)—West Pharmaceutical Services Inc. is expanding capacity to produce new syringe systems in Scottsdale, Ariz.
The Lionville-based firm has embarked on a multimillion dollar program to make the Daikyo Crystal Zenith 1ml, a syringe that overcomes problems with glass-based syringes, said Eric Resnick, vice president of engineering for West Delivery Systems. The program will be completed in the fourth quarter of 2011.
The new syringe system is injection molded from Daikyo Crystal Zenith, a cyclic polyolefin developed by West's Japanese partner Daikyo Seiko Ltd. The new products don't shatter or delaminate like glass syringes can, claims the company.
Resnick said that his firm is converting 32,000 square feet of space to Class 10,000 clean rooms for automated manufacturing. As well it will add testing laboratories and additional climate controlled warehouse space. It has already started the project and has added several new injection molding machines. At least six more will be installed for the program, according to Resnick.
Scottsdale was chosen for the syringe program because of its technical capabilities such as engineering, its in-house tool shop and a bank of injection molding presses. Scottsdale won out over West's three production plants in the Phoenix, Ariz., area.
“We found a high level of interest in the Crystal Zenith insert needle syringe system during its formal launch at a customer open house in Scottsdale last October,” saidd West Chairman and CEO Donald E. Morel in a news release. “The renovation project will give us the space for additional sophisticated injection molding technologies required for manufacturing Crystal Zenith syringes.”
Resnick did not reveal who will supply the injection presses for the expansion but he said Milacron, Arburg and Netstal presses fit its requirements.
In other news, publicly held West reported a decline in fourth quarter net income to $5.9 million from $20.3 million a year earlier. Sales at $276.8 million were 5.7-percent lower than in 2010. The company said non-recurring product sales, adverse currency effects and drawdown of customer inventories hurt results in the quarter.